Esperion to Participate in Upcoming Jefferies London Healthcare Conference
04 nov. 2024 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on...
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
31 oct. 2024 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations...
Esperion to Report Third Quarter 2024 Financial Results on November 7
24 oct. 2024 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024....
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
02 oct. 2024 08h00 HE
|
Esperion Therapeutics, Inc.
– Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From...
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
25 sept. 2024 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs)...
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
05 sept. 2024 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Cantor Global Healthcare Conference on...
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
03 sept. 2024 08h00 HE
|
Esperion Therapeutics, Inc.
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially...
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
26 août 2024 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment...
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
12 août 2024 06h00 HE
|
Esperion Therapeutics, Inc.
– Total Revenue Increased 186% Year-over-Year to $73.8 Million withU.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 août 2024 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under...